Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
| Brand name | CARVEDILOL |
| Generic name | CARVEDILOL |
| Active ingredient(s) | CARVEDILOL |
| Distributed by / for | Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA, NJ 07430 |
| NDC | 68462-162-05 |
| Full product label | Carvedilol Tablets, USP, 3.125 mg, Packaged as: a)500-count bottle, NDC 68462-162-05; b) 100-count bottle, NDC 68462-162-01; Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd, Colvale-Bardez, Goa, 403513, India. Manufactured for Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA, NJ 07430. |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | Nationwide in the USA |
| Quantity | 44,328 bottles |
| Recall initiated | 2025-08-07 |
| Report date | 2025-08-20 |
| Recall completed | — |
| Recall number | D-0577-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗